Journal
JOURNAL OF NEUROIMMUNOLOGY
Volume 215, Issue 1-2, Pages 90-95Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.jneuroim.2009.07.010
Keywords
Multiple sclerosis; T-bet; IL-17; RoR-gamma t; Type 1 immunity; Interferon-beta
Categories
Funding
- Ministry of Science of the Republic of Serbia [145066, 145045, 149041]
- Bayer Schering Pharma
Ask authors/readers for more resources
We studied the effect of one-year interferon (IFN)-beta treatment on the in vivo mRNA expression of IFN-gamma, interleukin (IL)-17, T-bet and RoR-gamma t, on peripheral blood mononuclear cells (PBMC) from 36 multiple sclerosis (MS) patients. In the total MS group, IFN-beta induced decrease in mRNA levels of IFN-gamma and T-bet (p<0.0001), while the levels of IL-17 and RoR-gamma t remained similar. In both responders and non-responders, IFN-beta induced significant decrease of IFN-gamma (p<0.0001 and p = 0.011, respectively), while decrease in T-bet was detected only in responders (p<0.0001). Higher pre-treatment T-bet allowed prediction of the clinical response in the first year (beta=0.601, p=0.036). Our preliminary findings suggest that T-bet expression might be a potential prognostic marker of treatment response to IFN-beta in MS. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available